Introduction to antifungal drugs

Clinical Infectious Diseases

Volumn 30, Issue 4, 2000, Pages 653-657

  Dismukes, W E ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANCOBAN; ANTACID AGENT; ANTIFUNGAL AGENT; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CYCLOSPORIN; DIDANOSINE; FLUCONAZOLE; FLUCYTOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ISONIAZID; ITRACONAZOLE; KETOCONAZOLE; LORATADINE; OMEPRAZOLE; PHENOBARBITAL; PHENYTOIN; POLYENE ANTIBIOTIC AGENT; PYRIMIDINE; PYRROLE; RIFAMPICIN; SUCRALFATE; SULFONYLUREA DERIVATIVE; TRIAZOLAM; TSUKUBAENOLIDE; UNINDEXED DRUG; WARFARIN;

ASPERGILLOSIS; CHILL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG METABOLISM; DRUG POTENTIATION; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; IMMUNE DEFICIENCY; NAUSEA; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMIC MYCOSIS; UNITED STATES; VOMITING;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; AZOLES; CANDIDA; DRUG APPROVAL; DRUG INTERACTIONS; HUMAN; MYCOSES; POLYENES; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0033796814     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313748     Document Type: Review

References (28)

1. Amphotericin B: 30 Years of clinical experience
2. Lipid formulations of amphotericin B: Recent progress and future directions
3. Lipid formulations of amphotericin B: Clinical efficacy and toxicities
4. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis
5. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases
6. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
7. Treatment of invasive fungal infections in renally impaired patients with amphotericin B colloidal dispersion
8. Liposomal amphotericin B for empiric therapy in patients with persistent fever and neutropenia
9. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS
10. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
11. Lipid formulations for amphotericin B: Does the emperor need new clothes?
12. Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion duration
13. Rapid intravenous infusion of amphotericin B: A pilot study
14. Prevention of amphotericin B-induced renal impairment: A review on the use of sodium supplementation
15. Pretreatment regimens for adverse events related to infusion of amphotericin B
16. Flucytosine
17. Evolving role of flucytosine in immunocompromised patients: New insights into safety, pharmacokinetics, and antifungal therapy
18. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
19. Overview of oral azole drugs as systemic anti-fungal therapy
20. Use of azoles for systemic antifungal therapy
21. Fluconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses
22. Fluconazole: An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients
23. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses
24. Drug interactions of systemic antifungal agents
25. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Development of intrepretative breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
26. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: Enhanced ability to detect amphotericin B-resistant Candida isolates
27. Do in vitro susceptibility data-predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia